Vertex drops VX-961 to continue search for perfect pain drug

Vertex has stopped development of VX-961 after getting a look at phase 1 data. The NaV1.8 inhibitor failed to meet Vertex’s desired pharmacokinetic and tolerability profile, leading it to dump the drug and outline plans to move a follow-up candidate into the clinic.